GlassScriptPhysician profile
Janelle C Cooper
NPI 1285950154
$3,352.70
in general payments reported to CMS, 2019-2025
27 companies · $708 in 2025
The $708 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $120 · 2021: $597 · 2022: $635 · 2023: $456 · 2024: $654 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.49 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $331.34 | 2021-2025 | Zurzuvae |
| Abbvie INC. | $324.57 | 2019-2024 | Lo Loestrin Fe, Orilissa, Liletta |
| Myovant Sciences INC. | $288.14 | 2021-2022 | |
| Hologic Sales and Service, LLC | $264.89 | 2021-2025 | Acessa Provu System, Aptima, Myosure Tissue Removal Device |
| Pfizer INC. | $255.20 | 2022-2025 | |
| Amgen INC. | $186.67 | 2019-2025 | Evenity, Prolia, Prolia |
| Astellas Pharma US INC | $174.99 | 2023-2024 | Veozah |
| Sumitomo Pharma America, INC. | $158.10 | 2023-2024 | Myfembree |
| Baxter Healthcare | $152.19 | 2021-2022 | |
| Aspira Women'S Health INC | $148.22 | 2021-2025 | Ova1 |
| Mayne Pharma Commercial LLC | $138.58 | 2024-2025 | |
| Exact Sciences Corporation | $135.97 | 2023-2025 | Cologuard Collection Kit |
| Exeltis, USA INC. | $102.87 | 2019-2025 | Slynd |
| Shield Therapeutics INC | $101.20 | 2023-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $93.19 | 2019-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $92.77 | 2024-2025 | Nexplanon |
| Therapeuticsmd, INC. | $89.13 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $74.01 | 2019-2020 | |
| Scynexis, INC. | $68.19 | 2022 | |
| Merck Sharp & Dohme LLC | $34.67 | 2019-2021 | |
| Evofem Biosciences, INC. | $31.05 | 2024-2025 | Phexxi, Solosec, Phexx |
| Millicent US INC | $29.88 | 2025 | Femlyv, Intrarosa |
| Supernus Pharmaceuticals, INC. | $20.43 | 2025 | Qelbree |
| Conmed Corporation | $16.27 | 2024 | Airseal, Vcare |
| Agile Therapeutics, INC. | $14.72 | 2021 | |
| Smith+Nephew, INC. | $13.55 | 2019 | |
| Meditrina | $11.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janelle Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.